Clinical Trial Update: A Study to Evaluate the Pharmacokinetics, Safety,and Efficacy of Omacetaxine Given Subcutaneously as a Fixed Dose in Patients With Chronic Phase (CP) or Accelerated Phase (AP) Chronic Myeloid Leukemia (CML) (Referred to as the SYNSINCT Study) [Phase 1, Phase 2]

View source ↗

Summary

A two-phase study evaluating subcutaneous omacetaxine in fixed dose for chronic phase or accelerated phase chronic myeloid leukemia has been terminated; results…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia

Drugs mentioned

• Omacetaxine (omacetaxine mepesuccinate)

Snippet

Sponsor: Teva Branded Pharmaceutical Products R&D, Inc. | Conditions: Chronic Myeloid Leukemia | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2019-01-14